Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis by Gregorini G et al.
Clinical Science Articles
Renal Apolipoprotein A-I Amyloidosis: A Rare and Usually
Ignored Cause of Hereditary Tubulointerstitial Nephritis
Gina Gregorini,* Claudia Izzi,* Laura Obici,† Regina Tardanico,‡ Christoph Ro¨cken,§
Battista Fabio Viola,* Mariano Capistrano,* Simona Donadei,† Luciano Biasi,
Tiziano Scalvini,¶ Giampaolo Merlini,† and Francesco Scolari*
*Division of Nephrology, ‡Pathology Department, Division of Infectious Diseases, and ¶Department of Internal
Medicine, Spedali Civili, Brescia, Italy; †Amyloid Center, Biotechnology Research Laboratories, IRCCS San Matteo,
Pavia, Italy; and §Department Pathology, Otto von Guericke University of Magdeburg, Magdeburg, Germany
Apolipoprotein A-I amyloidosis is a rare, late-onset, autosomal dominant condition characterized by systemic deposition of
amyloid in tissues, the major clinical problems being related to renal, hepatic, and cardiac involvement. Described is the
clinical and histologic picture of renal involvement as a result of apolipoprotein A-I amyloidosis in five families of Italian
ancestry. In all of the affected family members, the disease was caused by the Leu75Pro heterozygous mutation in exon 4 of
apolipoprotein A-I gene, as demonstrated by direct sequencing and RFLP analysis. Immunohistochemistry confirmed that
amyloid deposits were specifically stained with an anti-apolipoprotein A-I antibody. The clinical phenotype was mainly
characterized by a variable combination of kidney and liver disturbance. The occurrence of renal involvement seemed to be
almost universal, although its severity varied greatly ranging from subclinical organ damage to overt, slowly progressive renal
dysfunction. The renal presentation was consistent with a tubulointerstitial disease, as suggested by the findings of defective
urine-concentrating capacity, moderate polyuria, negative urinalysis, and mild tubular proteinuria. Histology confirmed
tubulointerstitial nephritis. Surprising, amyloid was restricted to nonglomerular regions and limited to the renal medulla.
This location of apolipoprotein A-I amyloid differs sharply from other systemic amyloidoses that are mainly characterized by
glomerular and vascular deposits. The tubulointerstitial nephritis as a result of hereditary apolipoprotein A-I amyloidosis is
a rare disease and a challenging diagnosis to recognize. Patients who present with familial tubulointerstitial nephritis
associated with liver disease require a high index of suspicion for apolipoprotein A-I amyloidosis.
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H ereditary systemic amyloidoses are late-onset, auto-somal dominant disorders caused by mutations inthe genes that encode a group of plasma proteins.
Originally classified by clinical presentation, progress in bio-
chemistry has made possible the classification of hereditary
amyloidoses according to the specific protein involved (1–3).
The most common form is transthyretin amyloidosis. Sequen-
tially, six other proteins have been associated with clinically
overt hereditary amyloidosis: Apolipoprotein A-I (apoA-I), cysta-
tin C, lysozyme, fibrinogen A-chain, gelsolin, and apoA-II (2).
ApoA-I is a 28-kd nonglycosylated protein that constitutes
the major apolipoprotein of HDL (4). In a mutated form, apoA-I
represents the amyloidogenic precursor in some cases of famil-
ial amyloidosis. N-terminal fragments of apoA-I, correspond-
ing to the first 83 to 93 residues, have been identified as the
main components of apoA-I amyloid fibrils (2). To date, 12
amyloidogenic apoA-I mutations that are associated with dep-
osition of amyloid fibrils predominantly in the liver, kidney,
and heart have been described; other tissues and organs that
are less frequently involved include the skin, the testes, the
larynx, and the peripheral nerves (5–17).
Recently, we reported 13 unrelated individuals from North-
ern Italy with a predominant hepatic amyloidosis associated
with a new apoA-I mutation indicated as Leu75Pro. In nine
patients, chronic renal failure also developed, but no kidney
biopsy was available at that time to elucidate the basis of this
renal dysfunction. We now report a detailed characterization of
the clinical and pathologic features of renal involvement ob-
served in five families with apoA-I amyloidosis associated with
the Leu75Pro substitution. Two of these kindreds were in-
cluded in the previous study (15), and three are new families.
Materials and Methods
Patients
Five families (Figure 1) who had hereditary apoA-I amyloidosis and
were native of the province of Brescia in Northern Italy were studied.
Families 1 and 3 have already been reported (Figure 1, Family D and
Family A [15]). Family trees were obtained by personal interview of the
patients and their relatives. Cyrillic software, version 2.1 (Cherwell
Scientific, Oxford, UK) was used for pedigree drawing and data col-
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lection. All individuals who participated in the study gave informed
consent according to the Helsinki declaration.
Diagnostic Criteria
Diagnosis of apoA-I amyloidosis was established on the basis of
family history, disease-related organ dysfunction, histologic demon-
stration of amyloid deposits on renal and/or hepatic tissue biopsy,
and detection of the mutation in the apoA-I gene. At-risk adult family
members were offered a presymptomatic genetic testing. Carriers of the
mutation underwent a clinical, laboratory, and instrumental assessment,
including renal and hepatic function tests and abdominal ultrasonogra-
phy.
The type of proteinuria was investigated using urinary protein elec-
trophoresis. The tubular pattern of proteinuria was defined by the
presence of a small albumin fraction (20% of total urinary protein)
and by the predominance of low molecular weight protein.
Figure 1. Family trees of 5 kindreds with apolipoprotein A-I (apoA-I) amyloidosis.
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Histology and Immunohistochemistry
Renal biopsy specimens were processed according to standard tech-
niques and examined by light microscopy and immunofluorescence
study. Detection of amyloid deposits was carried out through Congo
red staining, followed by microscopic examination under polarized
light. Immunohistochemical characterization of amyloid deposits was
performed on paraffin-embedded tissue sections using a panel of com-
mercial primary antibodies against known amyloid fibril proteins, in-
cluding  and  light chains, transthyretin, amyloid A, fibrinogen, and
apoA-I (Dako, Milano, Italy). The avidin-biotin complex method was
used to visualize the reaction.
Moreover, a peptide-antibody directed against apoA-I was generated
using NH2-DEPPQSPWDRVKDLAC-CONH2 and NH2-CVLKDS-
GRDYVSQFEG-CONH2 as immunogen as described elsewhere (18). IgG
was obtained by using HiTrap protein G columns (Amersham Pharmacia
Biotech, Freiburg, Germany). The specificity of the antibody was tested by
Western blotting using apolipoproteins that were purified from human
serum and by immunostaining of tissue sections from atherosclerotic
arteries with intimal amyloid deposits. No immunostaining was found
when the primary was omitted or replaced by preimmune serum. Immu-
nostaining of tissue sections was performedwith the anti–apoA-I antibody
(dilution 1:1500). Immunoreaction was visualized with the avidin-biotin
complex method applying a Vectastain ABC alkaline phosphatase kit
(Biogene-Alexis GmbH, Gru¨nberg, Germany). Neufuchsin served as chro-
mogen. The specimens were counterstained with hematoxylin.
Mutation Search in ApoA-I Gene
DNA was obtained, using standard procedures, from peripheral
blood mononuclear cells of affected and healthy at-risk family mem-
bers. Mutation detection was performed by direct sequencing of exons
and exon-intron boundaries of the apoA-I gene, as reported elsewhere
(15). RFLP analysis was performed to screen all at-risk family members
as described previously (15). After digestion of a 392-bp amplicon with
the restriction endonuclease HpaII, the occurrence of the mutation was
revealed on agarose gel electrophoresis by the presence of two addi-
tional fragments of 266 and 126 bp, respectively.
Results
Clinical Data
The pedigrees of the five families, including genetic testing
results, are shown in Figure 1. The overall clinical and biochem-
ical data are collected in Table 1.
Family 1
The proband (III-8) had a diagnosis of hepatitis C virus infection
at age 60. Hepatic biopsy showed mild active viral hepatitis and
amyloid deposits. Diagnosis of apoA-I amyloidosis was per-
formed at age 61 (15). At age 65, renal function was slightly
reduced, also when it was estimated using Cockcroft-Gault equa-
tion (65 ml/min). Urinalysis showed a reduced concentrating
ability and tubular proteinuria. Patient III-2, who had a history of
hypertension, moderate polyuria, and nocturia, first was seen at
age 53 with mild chronic renal failure; urinalysis was character-
ized by trace proteinuria and specific urine gravity of 1.010. A
renal biopsy, which contained only cortical tissue, revealed inter-
stitial fibrosis, tubular atrophy, and glomerular sclerosis; congo-
philic material was not detected. Immunofluorescence study was
negative. At age 58, because of mild elevation of alkaline phos-
phatase (ALP) and -glutamyl transpeptidase (GGT) during cho-
lecystectomy, he underwent liver biopsy that showed amyloid
deposits. At age 68, transesophageal echocardiography disclosed
increased myocardial thickness and speckled-appearing myocar-
dium, suggesting cardiac amyloidosis. Renal function progres-
sively declined, requiring peritoneal dialysis; urinalysis confirmed
mild proteinuria with a tubular pattern. One year later, he died of
liver failure. Patient III-4 underwent surgical excision of right
renal carcinoma at age 68. Chronic renal failure was documented;
urinalysis was negative except for the urine specific gravity of
1.010; an elevation of ALP and GGT was also observed. At age 76,
hepatosplenomegaly, portal hypertension, and a severe derange-
ment of liver enzymes were documented. At age 80, he was
referred for gastrointestinal hemorrhage. A sudden death oc-
curred. Patient IV-3 was referred at age 48 for hypertension and
chronic renal failure; urinalysis was negative; urine specific grav-
ity was 1.012. Renal biopsy provided a small fragment of renal
cortex showing interstitial fibrosis and tubular atrophy. The glo-
meruli revealed mild mesangial hypercellularity and no amyloid.
Immunofluorescence study was negative. At age 55, renal and
hepatic function were unchanged. Patient IV-4 was found at age
42 to have hypertension and chronic renal failure; urinalysis was
negative; urinary specific gravity was 1.010. In his history, at age
35, a gynecomastia required surgical treatment; endocrine inves-
tigation revealed hypergonadotropic hypogonadism secondary to
testicular failure. Renal biopsy that included only cortical tissue
was performed, showing a severe degree of interstitial fibrosis,
tubular atrophy, and glomerular sclerosis. Amyloid was not
found. Immunofluorescence study was negative. At age 48, hep-
atosplenomegaly and a significant increase of serum concentra-
tions of transaminases, ALP, and GGT were found. A liver biopsy
showed large nodular hepatic amyloidosis that specifically
stained with anti–apoA-I antibody.
Family 2
The proband (II-5) first was seen at age 56; she had a
history of hypertension, moderate polyuria, nocturia, and
chronic renal failure. Urinalysis showed small amounts of
proteinuria (270 mg/24 h) with tubular pattern and urinary
specific gravity of 1.010. Renal ultrasound and computed
tomography (CT) scan revealed reduced kidneys and med-
ullary cysts. A clinical diagnosis of medullary cystic kidney
disease was made. Renal biopsy, which contained only med-
ullary tissue, showed a diffuse interstitial amyloid deposi-
tion limited to the inner medulla and was associated with
tubular atrophy. At age 66, liver function tests suggested
cholestasis; liver biopsy confirmed portal amyloid deposits
that specifically stained with anti–apoA-I antibody. The pa-
tient died at age 70 yr of breast cancer. Patient II-1 was first
seen at age 58 with a history of hypertension, moderate
polyuria, nocturia, and chronic renal failure; urinalysis
showed trace proteinuria and a specific urinary gravity of
1.012. Renal ultrasound and CT scan showed moderately
reduced kidneys and small medullary cysts. At last follow-
up, at age 74, renal function was unchanged. Abdomen
ultrasound revealed smaller kidneys and hepatomegaly;
liver function tests revealed mild cholestasis. Patient II-6
presented at age 46 with a history of polyuria for many years;
mild chronic renal failure was found; urinalysis was negative
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except for urinary specific gravity of 1.012. Liver function
tests were normal. By renal ultrasound, kidney size was
moderately reduced.
Family 3
The proband (III-8) received a diagnosis at age 55 of apoA-I
amyloidosis on a liver biopsy that was performed because of
jaundice and persistent elevation of ALP and GGT (15). At age
63, renal function was slightly reduced and was confirmed (67
ml/min) using Cockroft-Gault equation. Urinalysis showed no
proteinuria or sediment abnormalities but reduced concentrat-
ing ability. Patient III-4 first was seen at age 51 for hyperten-
sion, mild reduction of renal function, and negative urinalysis
except for urinary specific gravity of 1.012. Three years later, as
a result of worsening of renal function and tubular proteinuria
(240 mg/24 h), she underwent renal biopsy. The renal cortex
showed several sclerotic glomeruli, interstitial fibrosis, tubular
atrophy, and no amyloid. However, in the inner medulla, ex-
tensive peritubular and interstitial amyloid deposition was
found. Coexistence of two different patterns of medullary amy-
loid deposition were observed: Peritubular ribbon-like deposits
and interstitial nodular areas, in association with tubular atro-
phy. Immunohistochemical staining of amyloid was specifi-
cally reactive to anti–apoA-I antibodies (Figure 2). Patient III-1
had a history of type 2 diabetes and hypertension. At age 65, he
underwent a liver biopsy, which was performed for chronic
hepatitis C and revealed mild active viral hepatitis and hepatic
amyloidosis. Renal function was slightly reduced; urinalysis
showed glomerular proteinuria (0.7 g/24 h), glycosuria, and
urinary specific gravity of 1.015. At last follow-up, at age 70,
renal and hepatic functions were unchanged.
Table 1. Clinical and biochemical features of patientsa
Pat ID
Gender/
Onset
Age (yr)
Hyp
Renal Involvement (Onset/Last Follow-up)
Hepatic
Involvement
Follow-Up
(yr)SCr
(mg/dl)
Cr Clear
(ml/min)
Proteinuria
(mg/d)
Pattern
of Prot
Urinary Specific
Gravity
(Normal Range
1.015 to 1.025)
Morning
Urinary
Osmol
(mmol/kg)
Renal
Biopsy
Kidney
Size
(US)
Family 1
III-2 M/53 Yes 1.8/10 50/10 Trace/400 Tub 1.010/1.008 300/290 Cortical tissue:
IF, TA, GS
Reduced Yes 16
III-4 M/68 Yes 1.6/3.2 58/20 Trace/trace ND 1.010/1.010 ND/ND ND Reduced Yes 12
III-8 F/60 Yes 0.8/1.05 nd/63 No/250 Tub Nd/1.012 Nd/320 ND Normal Yes 5
IV-3 M/48 Yes 2/2.3 40/37 No ND 1.012/1.010 320/300 Cortical tissue:
IF, TA, GS
Reduced No 7
IV-4 M/42 Yes 1.9/2 60/58 No ND 1.010/1.009 310/300 Cortical tissue:
IF, TA, GS
Reduced Yes 7
Family 2
II-1 F/58 Yes 2/2.5 40/35 Trace/trace ND 1.012/1.008 310/300 ND Reduced Yes 16
II-5 F/56 Yes 2.3/2.4 38/37 270/trace Tub 1.010/1.009 310/320 Amyloid
medullary
deposits
Reduced Yes 10
II-6 M/46 Yes 1.6/nd 56/nd No/ND — 1.012/ND 310/Nd ND Reduced No ND
Family 3
III-1 M/65 Yes 1.8/2.0 50/48 Trace/700 ND/glom 1.015/1.012 ND/ND ND Reduced Yes 5
III-4 F/51 Yes 1.3/1.7 nd/45 No/240 Tub 1.012/1.010 ND/310 Amyloid
medullary
deposits
Reduced No 4
III-8 M/55 Yes 1.1/1.3 nd/68 Trace/230 ND ND/1.012 ND/315 ND Reduced Yes 12
Family 4
II-1 M/56 Yes 1.6/2.3 ND/50 No/trace ND 1.012/1.010 ND/300 Amyloid
medullary
deposits
Reduced Yes 11
Family 5
II-1 M/54 Yes 1.8/1.9 45/42 Trace/240 Tub 1.015/1.014 400/390 Amyloid
medullary
deposits
Reduced Yes 1
aPat ID, patient identification number on pedigree; Hyp, hypertension; sCr, serum creatinine; Cr Clear, creatinine clearance
(normal values: men 90 ml/min; women 80 ml/min); US, ultrasound; M, male; F, female; ND, not done; tub, tubular;
glom, glomerular; IF, interstitial fibrosis; TA, tubular atrophy; GS, glomerular sclerosis.
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Family 4
The proband (II-1) first was seen at age 56 for hypertension
and mild chronic renal failure with negative urinalysis, except
for the urine specific gravity of 1.012. At age 64, he underwent
left nephrectomy for renal carcinoma. At age 67, for persistent
cholestasis, liver biopsy was performed and showed portal
amyloidosis. The re-evaluation of the nephrectomy specimens
disclosed small foci of amyloid deposits in the medullary in-
terstitium; moreover, in the inner medullary zones, the normal
parenchyma was replaced by a large band of amyloid (Figure
3A). Intense staining of amyloid deposits identified apoA-I as
the major amyloid fibril protein constituent. The renal cortex
did not contain amyloid. The adrenal glands were enlarged and
massively infiltrated with amyloid.
Family 5
The proband (II-1), who had a diagnosis of chronic hepatitis
C, was referred at age 64 because of hypertension and impaired
renal function. Urinalysis showed mild tubular proteinuria (240
mg/24 h). Liver function tests revealed mild cholestasis. Renal
biopsy showed a variable degree of glomerular sclerosis, inter-
stitial fibrosis, and tubular atrophy in the cortex. Immunofluo-
rescence study was negative. In the medulla, an isolated nod-
ular area of amyloid deposition was found (Figure 3B). Liver
biopsy revealed a chronic active hepatitis and apoA-I–immu-
noreactive amyloid deposits.
Discussion
Systemic amyloidoses are a well-recognized cause of glomer-
ular pathology and result in a progressive loss of urinary pro-
teins leading to nephrotic syndrome and to ESRD. In this
report, we detail the peculiar clinical, anatomic, and pathologic
features of kidney involvement in systemic apoA-I amyloid-
osis, in which the renal disease seems to differ sharply from
typical glomerulopathic systemic amyloidoses. Our findings
Figure 2. (A) Kidney biopsy specimen showing extensive peritubular and interstitial amyloid deposition in the inner medulla
(Congo red stain viewed under polarized light; areas of amyloid show apple green birefringence). (B and C) Kidney biopsy
specimen showing peritubular ribbon-like amyloid deposits in the inner medulla (periodic acid-Schiff stain) (D) Kidney biopsy
showing extended anti–apolipoprotein A-I (anti–apoA-I) immunoreactive amyloid deposits in the medulla. Magnification, 5 in
A; 25 in B and C; 40 in D.
Figure 3. (A) Nephrectomy specimen showing focal areas of amyloid deposition in the medullary interstitium; note in the inner
medulla a large band of amyloid material replacing normal parenchyma (hematoxylin-eosin stain). (B) Kidney biopsy specimen
showing microscopic appearance of an isolated metachromatic nodular amyloidotic area located in the inner medulla (crystal
violet stain). Magnification, 5.
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also expand previous knowledge on the natural history of this
autosomal dominant disorder, which recently was disclosed to
be prevalent in Italy (15) but has been also recognized in people
of various ethnic backgrounds (19).
The patients included in this study confirm our previous
observation of the relatively mild phenotype of the amyloid
disease associated with this apoA-I variant. Although the fibrils
localize also into the testes, heart, and adrenal glands, the
clinical picture seems to be dominated by either liver or kidney
disease, with onset varying from the fourth decade to advanced
age.
None of the families were known to be related to one an-
other; tracing family trees to at least the great-grandparents of
each index patient identified no ancestors shared by two or
more kindreds. However, the finding of the same mutation in
families who originated from different villages of the province
of Brescia raises the possibility that a common mutation have
been inherited from a shared ancestor (a founder mutation).
The identification of additional families who carry the mutation
and haplotype analysis will provide indication of whether the
disease is due to inheritance of the same mutation from a
common ancestor or to independent mutations.
Although the kidney involvement in hereditary apoA-I amy-
loidosis long has been clinically recognized, very few reports
have described the clinical and histologic picture (7,17). Thus,
our families give us the opportunity to outline some distinctive
aspects of the renal involvement that seem fragmentary in the
literature, such as the nature and frequency of the renal disease.
The renal disease invariably manifests as a tubulointerstitial
disorder, characterized by the occurrence of moderate polyuria
and nocturia as initial clinical signs, suggesting the presence of
an acquired, mild form of nephrogenic diabetes insipidus. Uri-
nalysis is frequently negative; proteinuria is a minor aspect of
the disease and shows a tubular pattern.
The frequency of the renal involvement seems to be almost
universal, although its severity varies greatly. The majority of
the patients had a slowly progressive renal dysfunction, and
only one reached end-stage renal failure. In a few patients with
predominant hepatic involvement and no overt renal disease, a
mild reduction in creatinine clearance was observed, associated
with a defective urine-concentrating ability. This suggests that
subclinical renal damage might be present in all f these patients,
consistent with a latent tubulointerstitial disease.
A major finding of our study was the medullary location of
amyloid. Histology confirmed that the renal disease was pri-
marily tubulointerstitial nephritis, characterized by tubular at-
rophy and interstitial fibrosis, with associated secondary focal
glomerular sclerosis. However, amyloid deposition was re-
stricted to nonglomerular regions and limited to the renal me-
dulla. The renal cortex did not contain amyloid, and a striking
absence of glomerular amyloid deposits was noted. The med-
ullary location probably explains why renal biopsy specimens
of the patients of family 1, which contained only cortical tissue,
did not show congophilic material. This remarkable selectivity
for the medullary compartment of apoA-I amyloid differs
sharply from the glomerular and vascular involvement of other
acquired and hereditary systemic amyloidoses (2). The only
exception is hereditary transthyretin amyloidosis, character-
ized by predominant medullary distribution of the renal amy-
loid deposits, which are mostly subclinical (20).
The medullary location of the apoA-I amyloid fibrils first was
described 30 yr ago, when the first variant of apoA-I
(Arg26Gly) was reported in the original Iowa family (17). Sub-
sequently, a few other reports confirmed that the renal involve-
ment of apoA-I was interstitial rather than glomerular (7,9). To
date, only one case of predominant glomerular involvement
with nephrotic syndrome as a result of apoA-I amyloidosis has
been reported (16), and this disparity in renal manifestations
remains to be explained.
Many general questions about formation and deposition of
any type of amyloidosis remain unanswered (1). In particular,
the mechanisms by which some mutant forms of apoA-I de-
posit as amyloid fibrils are still presently unknown and so are
the possible factors that govern the anatomic distribution of
apoA-I deposits, including this peculiar tropism for the renal
medulla. The biochemical characterization of ex vivo apoA-I
amyloid fibrils has invariably demonstrated that they are
formed by N-terminal fragments of mature apoA-I with signif-
icant C-terminal heterogeneity (21). This suggests that proteo-
lytic remodeling of mutant apoA-I is likely to play a relevant
role in the process of apoA-I fibrillogenesis. Although it is not
known where this proteolytic cleavage might occur and by
which proteases, mutations may enhance the amyloidogenic
propensity of this protein through destabilization of its native
structure (1). Such less stable conformation may be more sus-
ceptible to proteolysis, increasing the amyloidogenic precursor
protein pool.
A possible factor involved in the tissue localization of apoA-I
amyloid deposits could be related to the physiologic function of
apoA-I and to its metabolism. As the kidneys are the major
organ of HDL catabolism, locally elevated concentrations of the
amyloidogenic protein may result from specific interactions
with putative local receptors involved in HDL metabolism.
Moreover, peculiar local conditions, such as pH and osmolytes,
may play an additional role in modulating fibril formation.
Thus, the “renal medullary milieu,” characterized by high urea
concentrations and acidic pH, might act as an additional amy-
loidogenic hit, favoring amyloid formation (1,22). In the near
future, work on animal and cellular models will be of consid-
erable interest to understand the mechanism of preferential
deposition of this apoA-I variant in the medullary interstitium.
In summary, we have provided a detailed description of the
peculiar tubulointerstitial involvement observed in renal
apoA-I amyloidosis. Amyloid deposition is restricted to the
medullary interstitium and makes this disease indistinguish-
able on clinical grounds from other forms of hereditary tubu-
lointerstitial nephritis with prevalent medullary involvement,
such as medullary cystic kidney disease. The correct diagnosis
can be missed even in patients who undergo renal biopsy,
when the specimens contain only cortical tissue. Because renal
urinary concentration capacity might be altered early in pa-
tients with renal apoA-I amyloidosis, urinary concentration test
might be helpful for the early identification of these patients.
The diagnosis of renal tubulointerstitial disease as a result of
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apoA-I amyloidosis therefore represents a challenge. To meet
this challenge, nephrologists and pathologists alike will have to
maintain a high index of suspicion in patients who present with
familial tubulointerstitial renal disease associated with liver
involvement.
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